Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT02222922

NCT02222922
Completed Phase 1

Who may be able to join

Who might be able to join this trial:

For the every-2-weeks (Q2W) part of the trial:

  • You have been diagnosed with ovarian cancer that has stopped responding to platinum-based treatment and have received 2 or fewer previous treatments, OR you have advanced non-small cell lung cancer that has come back and have received 3 or fewer previous treatments
  • Your general health and ability to carry out daily activities meets a certain minimum level (rated 0, 1, or 2 on a standard scale)
  • Your blood counts, kidneys, and liver are functioning well enough to participate

For the every-3-weeks (Q3W) part of the trial:

  • You have a solid tumour that has spread and is no longer responding to standard treatment, or no standard treatment is available for your condition
  • Your general health and ability to carry out daily activities meets a certain minimum level (rated 0 or 1 on a standard scale)
  • Your blood counts, kidneys, and liver are functioning well enough to participate
  • The second part of this section specifically includes patients with ovarian cancer, triple negative breast cancer (with a specific protein marker), or non-small cell lung cancer

Who may not be able to join:

  • You have ovarian cancer that is not of the epithelial type, including a specific type called malignant mixed Mullerian tumours
  • You have a bowel blockage that has not been resolved
  • You have cancer that has spread to the brain and you are currently taking steroids to manage it
  • You have had major surgery, radiation therapy, or cancer drug treatment within the last 4 weeks before the trial would start
  • You currently have a significant active infection caused by bacteria, fungi, or a virus
  • (Q3W only) You have ovarian cancer and previously had radiotherapy to your pelvis or abdomen
  • (Q3W only) You have ovarian cancer that is only detectable through a blood marker called CA-125, with no measurable tumour visible on scans (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 1
Sponsor
Pfizer
Registry
clinicaltrials_gov
Start date
17 October 2014
Est. completion
5 November 2019

Where this trial is recruiting

🇪🇸 Spain 🇺🇸 United States

Primary endpoints

Number of Participants With Dose Limiting Toxicities (DLTs) - Q3W Regimen; Number of Participants With Treatment-Emergent Adverse Events (AEs) - Q3W Regimen (All-Causality); Number of Participants With Treatment-Emergent AEs - Q3W Regimen (Treatment-Related); Number of Participants With Treatment-Emergent AEs Categorized by Seriousness - Q3W Regimen (All-Causality and Treatment-Related); Number of Participants With Hematology Laboratory Abnormalities (All Cycles) - Q3W Regimen; Number of Participants With Chemistry Laboratory Abnormalities (All Cycles) - Q3W Regimen; Number of Participants Wit...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov